Azathioprine-induced Myelotoxicity After Switching Mesalazine Compound

Inflamm Bowel Dis. 2021 Aug 19;27(9):e114-e115. doi: 10.1093/ibd/izab102.

Authors

Marieke C Barnhoorn^{1

2}, Bert N Storm³, Nanne K de Boer⁴, Michael M P J A van der Voorn¹

Affiliations

¹ Department of Gastroenterology and Hepatology, HagaZiekenhuis, Den Haag, the Netherlands.
² Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands.
³ Department of Pharmacology, HagaZiekenhuis, Den Haag, the Netherlands.
⁴ Department of Gastroenterology and Hepatology, AGEM Research Institute, Amsterdam University Medical Center, VU University, Amsterdam, the Netherlands.

No abstract available

Keywords: drug interaction; inflammatory bowel disease; mesalazine; thiopurines.

Publication types

Case Reports

MeSH terms

Azathioprine* / adverse effects
Drug Substitution
Humans
Immunosuppressive Agents* / adverse effects
Inflammatory Bowel Diseases* / drug therapy
Mesalamine

Substances

Immunosuppressive Agents
Mesalamine
Azathioprine